Researchers at St. Jude developed a multiplex primer panel of chimeric sequences designed to amplify TCR αβ sequences in an unbiased manner, which allows for a highly efficient analysis of the TCR repertoire. The tractable and efficient set of primers can be used to isolate paired TCR αβ sequences at the single cell level from a variety of immune responses such as viral infections, tumors, and autoimmune patients, which can then be used to design effective immune cell-based therapies. The method offers an unbiased approach with low ambiguity in pairing and contamination over other assays being used.
cancer, immunology, chimeric antigen receptor (CAR), T cell, multiplex primer panel, chimeric sequences, TCR αβ sequences, immune response, viral infections, tumors, and autoimmune, immune cell-based therapies
Granted Patents or Published Applications
Application filed, available under confidentiality
Related Scientific References
St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: email@example.com.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.